1 – 6 of 6
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
(
- Contribution to journal › Article
- 2019
-
Mark
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
(
- Contribution to journal › Article
- 2017
-
Mark
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
(
- Contribution to journal › Article
-
Mark
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
(
- Contribution to journal › Article
- 2011
-
Mark
Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
(
- Contribution to journal › Article
- 2010
-
Mark
The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study
(
- Contribution to journal › Published meeting abstract